Your trusted source for investing success

Tag: press release

Looking for Cannabis Stocks?

Read our report to find market data, important news and stocks to watch!

Siemens and Partners Sign Joint Charter on Cybersecurity

Siemens (NQB:SIEGY) and eight partners announced at the Munich Cybersecurity Conference that they will sign the first joint charter for greater cybersecurity.

As quoted in the press release:
Initiated by Siemens, the Charter of Trust calls for binding rules and standards to build trust in cybersecurity and further advance digitalization. In addition

Glance Enters Automotive Vertical

Glance Technologies (CSE:GET; OTCQB:GLNNF) has announced it has signed with auto dealership company Blue Star Motors to offer its mobile payment solution Glance Pay.

As quoted in the press release:

“Providing a leading tech solution for our customers gives Blue Star Motors the ability to process payments wherever our customer is, with

AIT Therapeutics Announces $9.82 Million Private Placement

AIT Therapeutics (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announced that it has completed a private placement with a select group of investors, which, assuming the exercise of the Tranche A portion

BioStem Technologies Applies for Uplisting to the OTCQX Market

BioStem Technologies (OTC PINK: BSEM) a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine, announced today that it has completed its application to uplist on OTCQX, a higher tier Over The Counter market overseen by OTCMarkets.

As quoted in the press release:
Henry Van Vurst,

Travelan Revenue Grows Significantly in US and Australia

Immuron (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of many gut mediated diseases, is pleased to announce its half year sales results of its commercially available and over-the-counter gastrointestinal and digestive health supplement Travelan.

As quoted in the press release:
Immuron Marketing Manager

BioAmber Receives Notice of Delisting by TSX

BioAmber (OTCP:BIOA) has announced that the Toronto Stock Exchange (TSX) has notified the company that it will suspend the company’s trading of shares of common stock effective February 16 and to delist the company’s securities effective at market close on March 16.

As quoted in the press release:

These measures were taken

Sientra Launches New miraDry fresh Protocol for the miraDry System

miraDry a subsidiary of Sientra (NASDAQ:SIEN) a medical aesthetics company, today announced the launch of a new, improved treatment protocol for the miraDry system. Launching at the American Academy of Dermatology Annual Meeting  in San Diego, CA, February 16-18, 2018, the new miraDry freshprotocol reduces overall procedure time by up to

Cytokinetics Reports Fourth Quarter 2017 Financial Results

Cytokinetics (Nasdaq:CYTK) reported financial results for the fourth quarter of 2017. Net loss for the fourth quarter was $40.5 million, or $0.75 per basic share and diluted share, respectively, compared to net income for the same period in 2016 of $7.2 million, or $0.18 and $0.16 per basic and diluted

Moleculin Announces Pricing of $9 Million Registered Direct Offering

Moleculin Biotech (NASDAQ: MBRX) a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, announced that it has entered into a definitive agreement with institutional investors

Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros

Apricus Biosciences (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the U.S. Food and Drug Administration has issued a complete response letter for the New Drug Application of Vitaros™ a topical cream for the treatment of erectile dysfunction.

As quoted in the press release:
“We are

Amicus Therapeutics Prices Underwritten Offering of Common Stock

Amicus Therapeutics (Nasdaq:FOLD) announced the pricing of an underwritten offering of 19,354,839 shares of its common stock at $15.50 per share. The gross proceeds from the offering to Amicus are expected to be $300 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus.

As quoted in the press

Akcea Announces FDA Advisory Committee Meeting to Review Volanesorsen

Akcea Therapeutics (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced that the Division of Metabolism and Endocrinology Products of the U.S. Food and Drug Administration (FDA) will hold an advisory committee meeting to review

Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Option to Purchase Additional Shares

Affimed (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the closing of its previously announced public offering of 13,225,000 of its common shares at a public offering price of $2.00 per common share.

As quoted in the press release:

The total includes 1,725,000

Enter Your Log In Credentials
This setting should only be used on your home or work computer.


Privacy & Legal Policy

Privacy Policy

Investing News Network

Send this to a friend

I thought you might find this interesting:
Cannabis Weekly Round-Up: Two Provinces Reveal Deals in Place for Recreational Market